The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...

The Food and Drug Administration (FDA) has not approved ketamine as a treatment for any psychiatric disorder. The only FDA-approved option is Spravato, a nasal spray made from a derivative of ...

New Directions Mental Health's Greensburg clinic now offers SPRAVATO®, an FDA-approved nasal spray for fast relief from treatment-resistant depression. GREENSBURG, PA, UNITED STATES, March 26 ...

Spravato (esketamine) is prescribed for adults to treat: major depressive disorder (MDD), also called depression, with suicidal thoughts or actions treatment-resistant depression For MDD ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

It is not, however, a hopeless condition. A number of treatment approaches for TRD are available, including: Esketamine (Spravato) A nasal spray, Spravato won FDA approval on March 5, 2019 ...

TMS and Spravato Our compassionate team is committed to providing a safe, supportive environment where you can explore your treatment options and find the best path forward. Whether you’re ...

So SPRAVATO is indicated for treatment resistant depression. It is esketamine. It's a single enantiomer of ketamine. It's an intranasally administered compound. It was approved in 2019 for ...

My practice is integrated care for adults (psychiatric medication management, psychedelic esketamine (Spravato) treatments, primary care, weight loss injection therapy and asthetics). I am board ...

Johnson & Johnson has filed for FDA approval of its antidepressant nasal spray Spravato, hoping to make it the first standalone treatment for adults with treatment-resistant depression (TRD).